Key result
Neither the caspase inhibitor ZVAD-fmk nor the serine protease inhibitor DCI significantly reduced myocardial infarct size in rabbits, despite both significantly reducing DNA fragmentation in infarcted myocytes.
Why the study?
Does ZVAD-fmk or 3,4-dichloroisocoumarin reduce myocardial infarct size and DNA fragmentation in a rabbit model of ischemia-reperfusion?
Does ZVAD-fmk or 3,4-dichloroisocoumarin reduce myocardial infarct size and DNA fragmentation in a rabbit model of ischemia-reperfusion?
Inhibition of caspase or serine protease pathways reduces DNA fragmentation but does not reduce myocardial infarct size in a rabbit model of ischemia-reperfusion.
Answers are grounded in this paper and cite their sources.
Apoptosis inhibition reduces DNA fragmentation without limiting infarct size in rabbits; leaves open dominant mechanisms of myocyte death in ischemia-reperfusion.
Some infarcted myocytes undergo caspase-dependent DNA fragmentation, but serine protease-dependent DNA fragmentation may also be involved. There is controversy regarding whether caspase inhibitors can reduce infarct size, so the present study investigated whether serine protease inhibitor can reduce the DNA fragmentation of infarcted myocytes and whether serine protease or caspase inhibitors attenuates myocardial infarct size in Japanese white rabbits without collateral circulation. Rabbits were subjected to 30-min coronary occlusion followed by 48-h reperfusion. A vehicle (dimethylsulfoxide, control group, n=8) or Z-Val-Ala-Asp(Ome)-CH2F (ZVAD-fmk, a caspase inhibitor, ZVAD group, 0.8 mg/kg iv at 20 min before coronary occlusion and 0.8 mg/kg at 90 min after reperfusion, n=8) or 3,4-dichloroisocoumarin (DCI, a serine protease inhibitor, 2 mg/kg iv at 20 min before coronary occlusion, DCI group, n=8) was administered. Animals were killed at 48h after reperfusion for the detection of myocardial infarct size and at 4h after reperfusion for the detection of dUTP nick end-labeling (TUNEL)-positive myocytes, the electrophoretic pattern of DNA fragmentation and ultrastructural analysis. The left ventricle (LV) was excised and sliced. The myocardial infarct size as a percentage of the area at risk was assessed by triphenyltetrazolium chloride staining. DNA fragmentation was assessed by in situ TUNEL at the light microscopic level. ZVAD and DCI significantly reduced the mean blood pressure during reperfusion without affecting heart rate. There was no significant difference in the % area at risk (AAR) of LV among the 3 groups (control: 26.3+/-3.0%; ZVAD: 25.6+/-2.6%; DCI: 25.6+/-2.0%). The % infarct size as a percentage of the AAR in the ZVAD group (41.3+/-4.5%) and the DCI group (50.4+/-3.8%) was not significantly different from the control group (43.5+/-4.5%). However, the percent DNA fragmentation in the infarcted area in the ZVAD (3.5+/-0.8%) and DCI groups (4.2+/-0.9%) was significantly reduced compared with the control group (10.7+/-1.9%). The DNA ladder pattern observed in the control group was attenuated in both the ZVAD and DCI groups. There was no difference in electron microscopic changes among the 3 groups. Serine protease-dependent DNA fragmentation is present in infarcted myocytes, in addition to caspase-dependent DNA fragmentation, but an infarct-size reducing effect was not observed with either of these inhibitors.
No takes yet. Share an insight, caveat, or question.
Minatoguchi et al. (2001) studied Myocardial ischemia-reperfusion injury (n=31). ZVAD-fmk (caspase inhibitor) or DCI (serine protease inhibitor) vs. Vehicle (dimethylsulfoxide) was evaluated on Infarct size as a percentage of the area at risk (p=>0.05). Neither the caspase inhibitor ZVAD-fmk nor the serine protease inhibitor DCI significantly reduced myocardial infarct size in rabbits, despite both significantly reducing DNA fragmentation in infarcted myocytes.
Synapse has enriched 10 related papers. Consider them for comparative context: